Who
Richard Chin
Director
Company insider
Files Form 4 as: Director, Cytek Biosciences; Chief Executive Officer, Kindred Biosciences; Director, SELLAS Life Sciences Group; Director, ImmunoCellular Therapeutics; President and CEO, Oxigene.
In numbers
- Trades disclosed
- 148
- Buys
- 2
- Sells
- 24
- Bought
- $252K
- Sold
- $7.1M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 6 Jul 2006
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —6,107 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,107 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,107 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —6,107 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —33,333 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —18,261 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —33,333 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —18,261 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —6,107 | filing |
| 18 May 2026filed 20 May 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,107 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,107 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —6,107 | filing |
| 10 Mar 2026filed 12 Mar 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —6,107 | filing |
| 10 Mar 2026filed 12 Mar 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,107 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,107 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —6,107 | filing |
| 18 Nov 2025filed 20 Nov 2025 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,107 at $0.00 | filing |
| 18 Nov 2025filed 20 Nov 2025 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —6,107 | filing |
| 18 Aug 2025filed 20 Aug 2025 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —4,071 at $0.00 | filing |
| 18 Aug 2025filed 20 Aug 2025 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —4,071 | filing |
News
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Here's WhySLS · dailypolitical.com · 20 Oct 2026SELLAS Life Sciences Group (NASDAQ:SLS) Stock Falls 11.2% – Should You Sell?SLS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Richard Chin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.